Merial has announced a unique new indication for the highly selective canine NSAID Previcox. It is now licensed for the relief of pain and inflammation associated with dental surgery in dogs.
Merial has announced a unique new indication for the highly selective canine NSAID Previcox. The product is now licensed for the relief of pain and inflammation associated with dental surgery in dogs.
An estimated 70% of dogs over 2 years of age may have some degree of periodontal disease. Extraction of teeth is often necessary for the successful management of this condition and is regarded as a painful procedure.
The ability of Previcox to control the pain associated with dental surgery has recently been demonstrated in a double blinded, controlled trial in which dogs underwent maxillary canine tooth extraction.
The results showed that Previcox treatment significantly reduced pain scores post dental surgery, making it the only NSAID with a specific claim for relief of post-operative dental pain.
Results of physical examination and blood testing also confirmed the peri-operative safety profile of Previcox, with no treatment-related adverse effects noted during the trial.
According to the company, the benefits of Previcox include:
- Licensed for relief of pain and inflammation associated with osteoarthritis and soft tissue, orthopaedic and dental surgery;
- The first, and still the most selective, coxib NSAID for dogs;
- Rapid absorption means that peak plasma concentrations are reached within 90 minutes; and
- Safety and efficacy profile confirmed by clinical experience and supported by several published studies.
To find out more contact your Merial territory manager on 0870 6000 123 or visit www.previcoxfordogs.co.uk